FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896549191> ?p ?o ?g. }

• W2896549191 endingPage "e023830" @default.
• W2896549191 startingPage "e023830" @default.
• W2896549191 abstract "Objectives To compare population-based incidence rates of new-onset depression or self-harm in patients initiating incretin-based therapies with that of sulfonylureas (SU) and other glucose-lowering agents. Design Population-based cohort study. Setting Patients attending primary care practices registered with the UK-based Clinical Practice Research Datalink (CPRD). Participants Using the UK-based CPRD, we identified two incretin-based therapies cohorts: (1) dipeptidyl peptidase-4 inhibitor (DPP-4i)-cohort, consisting of new users of DPP-4i and SU and (2) glucagon-like peptide-1 receptor agonists (GLP-1RA)-cohort, consisting of new users of GLP-1RA and SU, between January 2007 and January 2016. Patients with a prior history of depression, self-harm and other serious psychiatric conditions were excluded. Main outcome measures The primary study outcome comprised a composite of new-onset depression or self-harm. Unadjusted and adjusted Cox proportional hazards regression was used to quantify the association between incretin-based therapies and depression or self-harm. Deciles of High-Dimensional Propensity Scores and concurrent number of glucose-lowering agents were used to adjust for potential confounding. Results We identified new users of 6206 DPP-4i and 22 128 SU in the DPP-4i-cohort, and 501 GLP-1RA and 16 409 SU new users in the GLP-1RA-cohort. The incidence of depression or self-harm was 8.2 vs 11.7 events/1000 person-years in the DPP-4i-cohort and 18.2 vs 13.6 events/1000 person-years in the GLP-1RA-cohort for incretin-based therapies versus SU, respectively. Incretin-based therapies were not associated with an increased or decreased incidence of depression or self-harm compared with SU (DPP-4i-cohort: unadjusted HR 0.70, 95% CI 0.51 to 0.96; adjusted HR 0.80, 95% CI 0.57 to 1.13; GLP-1RA-cohort: unadjusted HR 1.36, 95% CI 0.72 to 2.58; adjusted HR 1.25, 95% CI 0.63 to 2.50). Consistent results were observed for other glucose-lowering comparators including insulin and thiazolidinediones. Conclusions Our findings suggest that the two incretin-based therapies are not associated with an increased or decreased risk of depression or self-harm." @default.
• W2896549191 created "2018-10-26" @default.
• W2896549191 creator A5014210429 @default.
• W2896549191 creator A5059327282 @default.
• W2896549191 creator A5067563008 @default.
• W2896549191 creator A5089010927 @default.
• W2896549191 creator A5090793352 @default.
• W2896549191 date "2018-10-01" @default.
• W2896549191 modified "2023-10-16" @default.
• W2896549191 title "Examining the risk of depression or self-harm associated with incretin-based therapies used to manage hyperglycaemia in patients with type 2 diabetes: a cohort study using the UK Clinical Practice Research Datalink" @default.
• W2896549191 cites W1734094054 @default.
• W2896549191 cites W1909604994 @default.
• W2896549191 cites W1967862917 @default.
• W2896549191 cites W1979796529 @default.
• W2896549191 cites W1992023486 @default.
• W2896549191 cites W2000115601 @default.
• W2896549191 cites W2000417204 @default.
• W2896549191 cites W2002357983 @default.
• W2896549191 cites W2013488090 @default.
• W2896549191 cites W2025244593 @default.
• W2896549191 cites W2031908291 @default.
• W2896549191 cites W2033010452 @default.
• W2896549191 cites W2034460449 @default.
• W2896549191 cites W2035235507 @default.
• W2896549191 cites W2035344388 @default.
• W2896549191 cites W2037396061 @default.
• W2896549191 cites W2046667801 @default.
• W2896549191 cites W2050251015 @default.
• W2896549191 cites W2065014634 @default.
• W2896549191 cites W2065189444 @default.
• W2896549191 cites W2079396916 @default.
• W2896549191 cites W2080312294 @default.
• W2896549191 cites W2102694004 @default.
• W2896549191 cites W2119852447 @default.
• W2896549191 cites W2126919962 @default.
• W2896549191 cites W2131151951 @default.
• W2896549191 cites W2160313172 @default.
• W2896549191 cites W2163502113 @default.
• W2896549191 cites W2163589808 @default.
• W2896549191 cites W2164785151 @default.
• W2896549191 cites W2170913369 @default.
• W2896549191 cites W2191585320 @default.
• W2896549191 cites W2206575616 @default.
• W2896549191 cites W2292941967 @default.
• W2896549191 cites W2395634581 @default.
• W2896549191 cites W2468732910 @default.
• W2896549191 cites W2512868396 @default.
• W2896549191 cites W2564398793 @default.
• W2896549191 cites W2600604755 @default.
• W2896549191 cites W2790666678 @default.
• W2896549191 cites W4299591204 @default.
• W2896549191 cites W857664331 @default.
• W2896549191 doi "https://doi.org/10.1136/bmjopen-2018-023830" @default.
• W2896549191 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6194463" @default.
• W2896549191 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30297350" @default.
• W2896549191 hasPublicationYear "2018" @default.
• W2896549191 type Work @default.
• W2896549191 sameAs 2896549191 @default.
• W2896549191 citedByCount "14" @default.
• W2896549191 countsByYear W28965491912019 @default.
• W2896549191 countsByYear W28965491912020 @default.
• W2896549191 countsByYear W28965491912021 @default.
• W2896549191 countsByYear W28965491912022 @default.
• W2896549191 countsByYear W28965491912023 @default.
• W2896549191 crossrefType "journal-article" @default.
• W2896549191 hasAuthorship W2896549191A5014210429 @default.
• W2896549191 hasAuthorship W2896549191A5059327282 @default.
• W2896549191 hasAuthorship W2896549191A5067563008 @default.
• W2896549191 hasAuthorship W2896549191A5089010927 @default.
• W2896549191 hasAuthorship W2896549191A5090793352 @default.
• W2896549191 hasBestOaLocation W28965491911 @default.
• W2896549191 hasConcept C118552586 @default.
• W2896549191 hasConcept C120665830 @default.
• W2896549191 hasConcept C121332964 @default.
• W2896549191 hasConcept C126322002 @default.
• W2896549191 hasConcept C134018914 @default.
• W2896549191 hasConcept C139719470 @default.
• W2896549191 hasConcept C162324750 @default.
• W2896549191 hasConcept C201903717 @default.
• W2896549191 hasConcept C2776867660 @default.
• W2896549191 hasConcept C2777180221 @default.
• W2896549191 hasConcept C2778881409 @default.
• W2896549191 hasConcept C2908647359 @default.
• W2896549191 hasConcept C555293320 @default.
• W2896549191 hasConcept C61511704 @default.
• W2896549191 hasConcept C71924100 @default.
• W2896549191 hasConcept C72563966 @default.
• W2896549191 hasConcept C99454951 @default.
• W2896549191 hasConceptScore W2896549191C118552586 @default.
• W2896549191 hasConceptScore W2896549191C120665830 @default.
• W2896549191 hasConceptScore W2896549191C121332964 @default.
• W2896549191 hasConceptScore W2896549191C126322002 @default.
• W2896549191 hasConceptScore W2896549191C134018914 @default.
• W2896549191 hasConceptScore W2896549191C139719470 @default.
• W2896549191 hasConceptScore W2896549191C162324750 @default.
• W2896549191 hasConceptScore W2896549191C201903717 @default.
• W2896549191 hasConceptScore W2896549191C2776867660 @default.
• W2896549191 hasConceptScore W2896549191C2777180221 @default.

• next